Values as of: 2025-05-13
COMMON STOCK | Medical Devices |
Last Closing
USD 24.828Change
0.00 (0.00)%Market Cap
USD 22.19BVolume
6.66KAnalyst Target
N/AVerdict
Verdict
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides diagnostic imaging solutions, includes magnetic resonance imaging; X-ray systems; and computed tomography (CT) systems and software comprising detector-based spectral CT solutions; ultrasound imaging solutions focused on diagnosis, treatment planning and guidance for cardiac, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional X-ray systems and software solutions; and interventional image devices and software to aid in the diagnosis, navigation, treatment, and confirmation in minimally invasive interventional coronary, peripheral vascular, and hearth rhythm management procedures. The company also offers acute patient management solutions; emergency care solutions; patient care management in ambulatory and home care; sleep and respiratory care solutions; and vendor-agnostic software solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental and women's health solutions; and grooming and beauty products and solutions. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Company Website : https://www.philips.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ABT | Abbott Laboratories |
-2.94 (-2.23%) |
USD 220.05B |
| MDT | Medtronic PLC |
-0.70 (-0.82%) |
USD 106.32B |
| STE | STERIS plc |
-1.95 (-0.84%) |
USD 22.11B |
| ZBH | Zimmer Biomet Holdings Inc |
-0.73 (-0.74%) |
USD 20.08B |
| SNN | Smith & Nephew SNATS Inc |
-0.17 (-0.60%) |
USD 11.31B |
| PEN | Penumbra Inc |
-1.50 (-0.50%) |
USD 10.73B |
| GMED | Globus Medical |
-0.76 (-1.29%) |
USD 9.77B |
| BIO | Bio-Rad Laboratories Inc |
-3.53 (-1.38%) |
USD 6.94B |
| BIO-B | Bio-Rad Laboratories Inc |
+15.67 (+6.68%) |
USD 6.39B |
| GKOS | Glaukos Corp |
-2.28 (-2.41%) |
USD 5.15B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -1.67% | 63% | D | 40% | F | ||
| Dividend Return | 3.51% | 100% | F | 92% | A | ||
| Total Return | 1.84% | 66% | D+ | 63% | D | ||
| Trailing 12 Months | |||||||
| Capital Gain | -5.39% | 57% | F | 29% | F | ||
| Dividend Return | 3.38% | 100% | F | 60% | D- | ||
| Total Return | -2.01% | 57% | F | 29% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -37.95% | 28% | F | 10% | F | ||
| Dividend Return | 8.78% | 67% | D+ | 18% | F | ||
| Total Return | -29.17% | 28% | F | 9% | A- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -6.00% | 46% | F | 31% | F | ||
| Dividend Return | -6.00% | 45% | F | 29% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 38.52% | 73% | C | 59% | D- | ||
| Risk Adjusted Return | -15.58% | 43% | F | 29% | F | ||
| Market Capitalization | 22.19B | 93% | A | 92% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
